Medical Devices
-
Zimmer submits Monogram robot to FDA
The company is targeting Food and Drug Administration clearance next year for an autonomous orthopedic robot.
By Elise Reuter • Nov. 20, 2026 -
J&J to install first Ottava robot in US hospital
The commercial agreement with Memorial Hermann-Texas Medical Center comes in the same week that rival Medtronic revealed expanded FDA clearance for its Hugo robot in general surgical procedures.
By Susan Kelly • Nov. 20, 2026 -
Explore the Trendline➔
Sarah Silbiger via Getty Images
TrendlineTop 5 stories from MedTech Dive
From the effects of layoffs at the Food and Drug Administration and President Donald Trump’s tariff policies to the top medtech trends of 2026, here is a collection of top stories from MedTech Dive.
By MedTech Dive staff -
Abbott starts trial of Encantor transcatheter aortic valve
The balloon-expandable system could complement Abbott’s existing self-expanding Navitor device.
By Nick Paul Taylor • Nov. 20, 2026 -
Remedy Robotics raises $62M; Capstan’s mitral replacement robot progresses
Remedy plans a pivotal trial and has its sights on bringing to market a system for neurovascular intervention, while Capstan Medical performed the first U.S. transcatheter mitral valve replacement with its investigational robot.
By Susan Kelly • Nov. 18, 2026 -
Science Corporation raises $400M to commercialize BCI device
The device, which Science has launched in Europe, is designed to restore the sight of people with some forms of vision loss.
By Nick Paul Taylor • Nov. 18, 2026 -
Medtronic’s Hugo robot gets expanded FDA clearance in general surgery
The specialties gaining authorization account for more than half of the soft tissue procedures performed annually in the U.S.
By Susan Kelly • Nov. 17, 2026 -
Galvanize raises $130M to advance pulsed electric field ablation
The Series D round will support commercialization of Galvanize’s soft-tissue ablation platform and development of a chronic bronchitis device.
By Nick Paul Taylor • Nov. 17, 2026 -
Medtronic to buy Contego Medical for $380M
The deal is intended to expand Medtronic’s portfolio of carotid artery and peripheral vascular disease treatments.
By Susan Kelly • Nov. 16, 2026 -
Tandem wins FDA clearance for tubeless automated insulin delivery system
The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.”
By Nick Paul Taylor • Nov. 16, 2026 -
FDA posts early alerts for 2 product removals
Intersurgical told customers to immediately stop using affected devices, while Arrow International instructed users to quarantine and return certain products.
By Elise Reuter • Nov. 13, 2026 -
Olympus making strides on FDA quality concerns, CEO says
CEO Bob White said the endoscope manufacturer accelerated its remediation and quality improvement efforts to “provide the sustained evidence that the agency is expecting.”
By Susan Kelly • Nov. 13, 2026 -
J&J leads Francis Medical investment to fund prostate cancer device
With Johnson & Johnson’s support, Francis plans to take its water-vapor therapy device through the premarket approval process.
By Nick Paul Taylor • Nov. 12, 2026 -
Virtuoso robot wins FDA nod for bladder tumor removal
Virtuoso Surgical’s robotic system can remove lesions in one piece in a minimally invasive procedure designed to improve cancer diagnosis and staging.
By Susan Kelly • Nov. 10, 2026 -
Getinge hires president of acute care therapies
Stacy Beske joins Getinge from Philips and will take over the role on Dec. 1.
By Nick Paul Taylor • Nov. 10, 2026 -
Novocure denied FDA approval for metastatic cancer treatment
The FDA had uncertainty about the degree of clinical benefit for Novocure’s treatment of brain metastases, the company said.
By Elise Reuter • Nov. 9, 2026 -
FDA seeks input on telesurgery, autonomous robotics
The agency is inviting public comment on a new discussion paper as it prepares to shape policy covering robotic medical devices with autonomous or remote teleoperation functions.
By Susan Kelly • Nov. 9, 2026 -
Edwards bumps up sales forecast on TAVR strength in Q3
Going forward, the heart valve maker expects procedure volumes to rise following positive study data and expanded Medicare reimbursement.
By Susan Kelly • Nov. 5, 2026 -
Boston Scientific, Blackstone agree to $455M deal to co-fund heart pump development
As part of the agreement, Blackstone may receive regulatory and commercial milestone payments, plus royalties on net sales.
By Nick Paul Taylor • Nov. 5, 2026 -
MiniMed names David Segal chief medical officer
Segal is succeeding Robert Vigersky, who is transitioning to a chief medical officer emeritus role ahead of his planned retirement at the end of next year.
By Nick Paul Taylor • Nov. 5, 2026 -
Zimmer raises sales forecast despite slower knee business
CEO Ivan Tornos did not attribute the company’s performance in knees to a broader market slowdown, as competitor Stryker did last week.
By Elise Reuter • Nov. 4, 2026 -
Philips settles with DOJ over recalled CPAP machines
Philips will pay 288 million euros to settle an investigation related to its recall of millions of sleep and respiratory devices.
By Elise Reuter • Nov. 4, 2026 -
3 takeaways from TCT 2026
Edwards’ TAVR results in moderate aortic stenosis drew applause from meeting attendees, while Medtronic’s renal denervation and Abbott’s left atrial appendage closure devices also produced positive study findings.
By Susan Kelly • Nov. 4, 2026 -
Q&A
AdvaMed Chair Mick Farrell shares his top priorities, challenges for the medtech industry
In a year where companies are grappling with cyberattacks, inflation and potential tariffs, Farrell, who is also CEO of Resmed, shared a bird’s eye view of the issues.
By Elise Reuter • Nov. 2, 2026 -
Abbott starts pivotal trial for mitral valve replacement device
The study is testing a device that Abbott executives believe can expand the mitral valve market.
By Nick Paul Taylor • Nov. 2, 2026 -
FDA posts alert about Medline beds linked to 2 deaths
The company notified customers this month that it will discontinue Medline brand beds and associated products and exit the market.
By Nick Paul Taylor • Oct. 30, 2026